<--- Back to Details
First PageDocument Content
Medicine / Immunology / Clinical medicine / Health care / Immunosuppressants / Biotechnology / Monoclonal antibodies / Immune system / Immunogenicity / Autoimmunity / Infliximab / Arthritis
Date: 2015-06-19 09:16:17
Medicine
Immunology
Clinical medicine
Health care
Immunosuppressants
Biotechnology
Monoclonal antibodies
Immune system
Immunogenicity
Autoimmunity
Infliximab
Arthritis

TABLE OF CONTENTS INTRODUCTION 2

Add to Reading List

Source URL: www.abirisk.eu

Download Document from Source Website

File Size: 871,31 KB

Share Document on Facebook

Similar Documents

CONTACT: Media: Charlene McGrady, extMDS Pharma Services Scientist to Discuss Development of Biosimilar Monoclonal Antibodies at EGA Symposium

DocID: 1vhgc - View Document

ABIRISK ABIRISK Project Officially Started A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments for

DocID: 1v3WA - View Document

Celartia Protocols Hybridoma Cell culture with Petaka-HOT (High Oxygen Turnover, orange port) Production of Monoclonal Antibodies Petaka-HOT allows culturing non adherent

DocID: 1uTpm - View Document

INTERNSHIP PROPOSAL Institute and Group: IBS group HIV and persistent human viruses Supervisor: Pascal Poignard Email: Research project title: Human monoclonal antibodies: a new therapeutic strategy

DocID: 1uPEI - View Document

Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT – Expands Company’s Therapeutic Pipeline for Infectious Diseases – Cambridge, MA – December 2, 2013 – Visterra,

DocID: 1ujGa - View Document